NCCN Guidelines for Patients® | Diffuse Large B-cell Lymphoma

45 NCCN Guidelines for Patients ® : Diffuse Large B-cell Lymphoma, 2017 Blood stem cell transplant is not planned What are the options? • Clinical trial • Drug treatment ◦◦ Bendamustine ± rituximab ◦◦ Brentuximab vedotin for CD30+ disease ◦◦ CEPP ± rituximab ◦◦ CEOP ± rituximab ◦◦ DA-EPOCH ± rituximab ◦◦ GDP ± rituximab ◦◦ GemOx ± rituximab ◦◦ Lenalidomide ± rituximab ◦◦ Rituximab ◦◦ Other cancer drugs to treat CNS disease may also be received • Radiation therapy • Best supportive care 4 Treatment guide Second-line treatment | Review Guide 8. Second-line treatment Blood stem cell transplant is planned Immunochemotherapy Results Treatment • DHAP ± rituximab • ESHAP ± rituximab • GDP ± rituximab • GemOx ± rituximab • ICE ± rituximab • MINE ± rituximab Other cancer drugs to treat CNS disease may also be received No signs of cancer or cancer looks smaller • Autologous blood stem cell transplant ± involved-site radiation therapy • Clinical trial • Allogeneic blood stem cell transplant in some cases Cancer looks the same or larger • Clinical trial • Drug treatment • Radiation therapy • Best supportive care

RkJQdWJsaXNoZXIy MTE3MTE1